Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and raises the price target from $22 to $24.
June 21, 2023 | 4:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Catalyst Pharmaceuticals and raises the price target from $22 to $24.
The news of Truist Securities maintaining a Buy rating and raising the price target for Catalyst Pharmaceuticals (CPRX) from $22 to $24 indicates a positive outlook for the company's stock. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100